Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Fusidic Acid→

Fusidic Acid Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
6990-06-3
Molecular formula
C31H48O6
Molecular weight
516.7 g/mol
Drug class
Steroidal-structure antibioticelongation factor G (EF-G) inhibitor
Mechanism of action
Binds bacterial elongation factor G (EF-G) and prevents its release from the ribosome after translocation, inhibiting protein synthesis and bacterial growth.
Indications / reported uses
  • Topical treatment of localised bacterial skin infections caused by susceptible Staphylococcus aureus, including impetigo and infected dermatitis, with authorised topical formulations
  • Systemic treatment of serious susceptible staphylococcal infections in selected jurisdictions and formulations; topical and systemic indications are not interchangeable

Sources: NHS — Fusidic acid · NLM MeSH — Fusidic acid · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Fusidic Acid Environmental Risk Assessment (ERA) (the Fusidic Acid ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.